ArticleTranslational oncology2026
Machine learning derived ORC6 as a hub biomarker for predicting tumor microenvironment, prognoses, and therapeutic responses in lung adenocarcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The origin recognition complex (ORC) is a DNA-binding complex composed of six subunits involved in DNA replication in cancer cells. The prognostic and immunological implications of ORC6 in lung adenocarcinoma (LUAD) are not yet clear. This study utilizes multiple databases (such as TCGA, GEO, GTEx, etc.) to investigate the potential significance of ORC6 in LUAD. The results show that high ORC6 expression is associated with advanced disease and poorer prognosis and is involved in biological processes such as cell cycle regulation, DNA replication, and signal transduction. The expression of ORC6 correlates negatively with the infiltration of CD4+ and CD8+ T cells but positively with the infiltration of cancer-associated fibroblasts and endothelial cells. Additionally, a positive correlation between ORC6 and immunosuppression-related genes (such as LAG3 and PDCD1) was found. Validation of ORC6 expression was conducted through qRT-PCR, western blotting, and immunofluorescence, indicating its potential diagnostic, prognostic, and therapeutic value in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.